Review




Structured Review

Guardant Health guardant360 platform
Guardant360 Platform, supplied by Guardant Health, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/guardant360+platform/cdx+guardant360/pmc13068569-50-6-9
Average 86 stars, based on 1 article reviews
guardant360 platform - by Bioz Stars, 2026-09
86/100 stars

Images

Related Articles

other:

Article Title: Immunotherapy Plus Locoregional Therapy Leading to Curative-Intent Hepatectomy in HCC: Proof of Concept Producing Durable Survival Benefits Detectable with Liquid Biopsy.
Article Snippet: Patients now receive standard-of-care ctDNA draws within 30 days preoperatively, 30–60 days postoperatively, and q3–6 months thereafter (Figure 1). ctDNA was obtained using the Guardant360 platform (Guardant Health, Redwood, CA, USA).

Article Title: Immunotherapy Plus Locoregional Therapy Leading to Curative-Intent Hepatectomy in HCC: Proof of Concept Producing Durable Survival Benefits Detectable with Liquid Biopsy
Article Snippet: Patients now receive standard-of-care ctDNA draws within 30 days preoperatively, 30–60 days postoperatively, and q3–6 months thereafter ( ). ctDNA was obtained using the Guardant360 platform (Guardant Health, Redwood, CA, USA).

Next-Generation Sequencing:

Article Title: Prognostic Biomarkers and Immunotherapeutic Insights of Circulating Tumor DNA Analysis in Advanced Esophageal Squamous Cell Carcinoma From SCRUM-MONSTAR GOZILA Substudy
Article Snippet: PURPOSE Advanced esophageal squamous cell carcinoma (ESCC) has a poor prognosis, and current treatments provide limited survival benefits.. This study aimed to identify prognostic biomarkers and therapeutic targets by genomic profiling of advanced ESCC using circulating tumor DNA (ctDNA).. METHODS The SCRUM-MONSTAR GOZILA study is a nationwide, plasma-based molecular profiling project using Guardant360, involving 31 core cancer institutions in Japan.

Article Title: Prognostic Biomarkers and Immunotherapeutic Insights of Circulating Tumor DNA Analysis in Advanced Esophageal Squamous Cell Carcinoma From SCRUM-MONSTAR GOZILA Substudy
Article Snippet: .. NGS analysis of plasma ctDNA from GOZILA study participants was performed using the Guardant360 platform at Guardant Health. ..

Clinical Proteomics:

Article Title: Prognostic Biomarkers and Immunotherapeutic Insights of Circulating Tumor DNA Analysis in Advanced Esophageal Squamous Cell Carcinoma From SCRUM-MONSTAR GOZILA Substudy
Article Snippet: PURPOSE Advanced esophageal squamous cell carcinoma (ESCC) has a poor prognosis, and current treatments provide limited survival benefits.. This study aimed to identify prognostic biomarkers and therapeutic targets by genomic profiling of advanced ESCC using circulating tumor DNA (ctDNA).. METHODS The SCRUM-MONSTAR GOZILA study is a nationwide, plasma-based molecular profiling project using Guardant360, involving 31 core cancer institutions in Japan.

Article Title: The incremental value of liquid biopsy in the initial evaluation of patients with metastatic non-small cell lung cancer undergoing tissue-based molecular testing
Article Snippet: Tissue-based testing was completed using in-house and proprietary next-generation DNA and RNA sequencing (Comprehensive Solid Tumor HaloPlex HS , version 2.0; Agilent Technology, Inc). .. Plasma-based molecular sequencing utilized the proprietary Guardant360 platform from Guardant Health with an established concordance of >77% with tissue-based testing [ , ]. .. Blood samples were collected from patients in clinic as part of routine care and mailed to an outside lab as per Guardant Health's established protocols.

Article Title: Prognostic Biomarkers and Immunotherapeutic Insights of Circulating Tumor DNA Analysis in Advanced Esophageal Squamous Cell Carcinoma From SCRUM-MONSTAR GOZILA Substudy
Article Snippet: .. NGS analysis of plasma ctDNA from GOZILA study participants was performed using the Guardant360 platform at Guardant Health. ..

Sequencing:

Article Title: The incremental value of liquid biopsy in the initial evaluation of patients with metastatic non-small cell lung cancer undergoing tissue-based molecular testing
Article Snippet: Tissue-based testing was completed using in-house and proprietary next-generation DNA and RNA sequencing (Comprehensive Solid Tumor HaloPlex HS , version 2.0; Agilent Technology, Inc). .. Plasma-based molecular sequencing utilized the proprietary Guardant360 platform from Guardant Health with an established concordance of >77% with tissue-based testing [ , ]. .. Blood samples were collected from patients in clinic as part of routine care and mailed to an outside lab as per Guardant Health's established protocols.



Similar Products

86
Guardant Health guardant360 platform
Guardant360 Platform, supplied by Guardant Health, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/guardant360+platform/cdx+guardant360/pmc13068569-50-6-9
Average 86 stars, based on 1 article reviews
guardant360 platform - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier

90
Guardant Health next-generation sequencing–based 74-gene guardant360 platform
Next Generation Sequencing–Based 74 Gene Guardant360 Platform, supplied by Guardant Health, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/guardant360+platform/guardant360/pmc12260505-146-10-13
Average 90 stars, based on 1 article reviews
next-generation sequencing–based 74-gene guardant360 platform - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
Guardant Health guardant360® platform
Guardant360® Platform, supplied by Guardant Health, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/guardant360+platform/guardant360/pmc10915757-139-30-32
Average 90 stars, based on 1 article reviews
guardant360® platform - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
Guardant Health guardant360 cdx platform
a , Heatmap of genetic alterations detected using <t>Guardant360</t> CDx. b , Progression-free survival and overall survival according to the presence of genetic alterations in the Wnt/β-Catenin pathway, evaluated by circulating tumor DNA analysis. Two-sided Log-rank test was used for comparison.
Guardant360 Cdx Platform, supplied by Guardant Health, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/guardant360+platform/guardant360/pmc10957471-296-12-15
Average 90 stars, based on 1 article reviews
guardant360 cdx platform - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

Image Search Results


a , Heatmap of genetic alterations detected using Guardant360 CDx. b , Progression-free survival and overall survival according to the presence of genetic alterations in the Wnt/β-Catenin pathway, evaluated by circulating tumor DNA analysis. Two-sided Log-rank test was used for comparison.

Journal: Nature Medicine

Article Title: Regorafenib plus nivolumab in unresectable hepatocellular carcinoma: the phase 2 RENOBATE trial

doi: 10.1038/s41591-024-02824-y

Figure Lengend Snippet: a , Heatmap of genetic alterations detected using Guardant360 CDx. b , Progression-free survival and overall survival according to the presence of genetic alterations in the Wnt/β-Catenin pathway, evaluated by circulating tumor DNA analysis. Two-sided Log-rank test was used for comparison.

Article Snippet: Using baseline samples of all 42 patients, ctDNA was analyzed using the Guardant360 CDx platform (Guardant Health).

Techniques: Comparison